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Summary. We determined the adrenostatic poten-
tial of low-dose nonhypnotie etomidate in six pa-
tients with Cushing's syndrome (ectopie Cushing's 
syndrome, n=2; Cushing's disease, n 3; bilateral 
adrenal adenoma, n = 1). Etomidate was given as 
a continuous infusion for 32 hin a dose of 2.5 mg/ 
h (n = 5) or 0.3 mg/kg/h (n = 3), respectively. Saline 
was given during a control period. The responsive-
ness to exogenous ACTH was studied during pla-
cebo and 7 and 31 h after commencing etomidate 
by administration of 250 ~g 1-24 ACTH Lv. Eto-
midate (2.5 mg/h) led to a consistent decrease in 
serum cortisol in all patients from a me an of 
39.4±13.3 to 21.1 ±5.7 ~g/dl after 7 h (P<0.05 
compared with placebo). After 24 h cortisol was 
reduced further to a mean steady state concentra-
tion of 12.3±5.7 ~g/dl (P<0.05). At the end of 
the infusion period the cortisol increase in response 
to ACTH was reduced but not abolished. In con-
trast, a dose of 0.3 mg/kg/h etomidate induced un-
responsiveness of serum cortisol to exogenous 
ACTH within 7 h. However, sedation was obser-
ved in two out of three patients at this dose, while 
during etomidate in a dose of 2.5 mg/h no side 
effects were seen. We conc1ude that low-dose non-
hypnotic etomidate reduces serum cortisol to with-
in the normal range in patients with Cushing's 
syndrome. The possibility to dissociate the adreno-
static effect of etomidate from its hypnotic action, 
the absence of side effects, and the i.v. route sug-
gest that etomidate in a dose of 0.04-0.05 mg/kg/h 
may become the drug of choice for rapid initial 
control of hypercortisolism. 
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During recent years it has been shown that the 
anesthetic drug etomidate is also a potent adreno-
statie agent [2, 3, 5, 7, 8, 12, 13, 17, 19]. Etomidate 
blocks the cytochrome P450-dependent adrenal en-
zymes 11 ß-hydroxylase and cholesterol-side-chain 
cleavage enzyme [3, 5, 8, 12, 19]. Using dispersed 
guinea-pig adrenal cells, etomidate has been pro-
ved to be the most powerful adrenostatic drug 
available [13]. In this system a mean etomidate 
concentration of 97 nmol/l was required for 50% 
inhibition of cortisol secretion [13]. This is conside-
rably lower than the target mean plasma concen-
tration of 560 nmol/l to induce sedation [10]. Ac-
cordingly after a single induction dose of etomidate 
(0.3 mg/kg body weight) the adrenocortical block-
ade lasts several hours [2, 7], while the hypnotic 
action of etomidate rapidly fades. Using low 
plasma concentrations it should, therefore, be pos-
sible to dissociate the adrenostatic action of etomi-
date from the hypnotic properties of the com-
pound. This was successfully demonstrated in a 
small number of normal subjects by Engelhardt 
et al. [6] using a bolus dose of 0.03 mg/kg body 
weight followed by a continuous infusion of etomi-
date at a dose of 0.3 mg/kg/h. 
The aim of the present study was to evaluate 
the adrenostatic potential of low-dose nonhypnotic 
etomidate in the treatment of patients with Cush-
ing's syndrome. The efficacy of hypnotic doses of 
etomidate in reversing hypercortisolemia has been 
proved recently [9]. 
Patients and Methods 
A total of six patients with Cushing's syndrome 
was studied (1 male, 5 females, aged 37 to 54 
years). Cushing's syndrome was diagnosed by de-
xamethasone nonsuppressible serum cortisol, ele-
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Table 1. Clinical data of the six patients with Cushing's syn-
drome 
Patient Age Sex Body Baseline (9:00 h) Diagnosis 
(years) Weight 
(kg) Plasma Serum 
ACTH cortisol 
(pg/ml) (Jlg/dl) 
1 43 M 73.1 358 22.0 Ectopic CS 
2 37 F 62.4 152 106.3 Ectopic CS 
3 52 F 68.5 21 23.8 CD 
4 39 F 72.8 27 56.1 CD 
5 54 F 92.7 38 39.5 CD 
6 47 F 74.3 <5 28.5 Bil. adrenal 
adrenomaa 
a Studied after unilateral adrenalectomy 
M, male; F, female; CS, Cushing's syndrome; CD, Cushing's 
disease 
vated urinary free cortisol, and altered diurnal 
rhythm of cortisol as assessed by measurements 
of salivary free cortisol. Two of the six patients 
suffered from the ectopic ACTH syndrome due 
to a medullary carcinoma of the thyroid and a 
carcinoid ofunknown primary site with liver meta-
stases, respectively. One patient had bilateral adre-
nal adenomas and was studied 4 months after uni-
lateral adrenalectomy. The remaining three pa-
tients had Cushing's disease. Patient data are given 
in Table 1. 
Protocol: The patients were studied during 3 con-
secutive days. On day 1 placebo (0.9% saline) was 
given intravenously over 8 h. On day 2 a conti-
nuous infusion of etomidate (2.S mg/h) was started 
at 8:00 hand continued until 16:00 h of day 3 
(infusion period 32 h; n = S). In addition, in three 
patients ACTH stimulation tests (2S0 llg 1-24 
ACTH as bolus dose intravenously) were perfor-
med at lS: 00 h on the 3 consecutive days. 
Three patients underwent a similar protocol 
with the dose of etomidate increased to 0.3 mg/kg/ 
h. In case ofhypnotic side effects the dose of etomi-
date was reduced by SO%. 
Blood sampies were collected in hourly inter-
vals from 8:00 h until 16:00 h during the 3 days 
of the study. Serum cortisol and ll-deoxycortisol 
were measured by radioimmunoassay using com-
mercially available reagents (NEN, Dreieich, DRG 
Instruments, Marburg, FRG), plasma ACTH was 
determined by radioimmunoassay [1] after extrac-
tion with QUSO G 32 [18]. 
Statistical evaluation was performed using Stu-
dent's t-test for paired data. 
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Fig. 1. Basal (n 5) and stimulated (n = 3) serum cortisol in 
Cushing's syndrome during saline (.-.), after commencing 
etomidate (2.5 mg/h; 0-0), and under steady-state conditions 
(.-.) (* P<0.05) 
Results 
Baseline serum cortisol concentrations ranged be-
tween 22.0 and 106.3 llg/dl, with th;e highest con-
centrations in the patient with ectopic ACTH sec-
retion due to a medullary carcinoma of the thyroid. 
As expected, no change in serum cortisol levels 
was observed during administration of saline. Af-
ter commencing low dose etomidate (2.S mg/h) a 
continuous fall of serum cortisol was observed in 
all subjects from a mean of 39.4 ± 13.3 to 
21.1 ±S.7 llg/dl (x±SEM) at lS:00 h (P<O.OS). 
On day 3 serum cortisol was reduced further 
to 12.3±S.711g/dl at 8:00h (P<O.OS compared 
to placebo) and remained unchanged during the 
rest of the infusion period, indicating that steady-
state conditions had been reached (Fig. 1). Stimu-
lation with ACTH induced an increase in serum 
cortisol of 28.6 ± 7.9 llg/dl during placebo, which 
was not influenced by an 8-h infusion of etomidate 
(LI cortisol: 28.5 ± 8.3 llgjdl). However, on day 3 
at the end of the infusion period the cortisol in-
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Fig.2. Basal and stimulated serum cortisol in three patients 
with Cushing's syndrome during saline (e-e), after commen-
eing etomidate (0.3 mg/kg/h; 0-0), and under steady-state 
eonditions (0.15-0.3 mg/kg/h; .-.) 
crease after ACTH was diminished to 13.6 ± 3.9 Ilgj 
dl (Fig. 1). 
The pattern of the cortisol response to etomi-
date was very similar when an initial dose of 
0.3 mgjkgjh was used with a dec1ine from 
72.1 ±30.4llgjdl to 29.3±8.3Ilgjdl at 15:00 h af-
ter the start of etomidate and steady-state concen-
trations of 11.2 ± 2.4 Ilgjdl on day 3 (Fig. 2). How-
ever, in contrast to a dose of 2.5 mgjh, the higher 
dose of etomidate completely blocked the cortisol 
response to exogenous ACTH (Fig. 2). During ad-
ministration of 0.3 mgjkgjh etomidate a slight se-
dation was noticed in two of the three patients, 
which rapidly disappeared after reduction to 
0.15 mgjkgjh. Basal plasma ACTH concentrations 
ranged from undetectable (in the patient with bila-
teral adrenal adenoma) to 358 pgjml. No consis-
tent change of plasma ACTH concentrations was 
observed in any single patient, in particular no 
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ACTH increase was demonstrated in the three pa-
tients with Cushing's disease. 
Baseline serum I1-deoxycortisol concentra-
tions ranged from 3.8 to 18.3 ngjml during placebo 
and consistently increased during etomidate infu-
sion to a variable extent reaching maximum values 
between 75 ngjml (adrenal adenoma) and 452 ngj 
ml (ectopic ACTH syndrome). During 2.5 mg eto-
midatejh l1-deoxycortisol rose from 9.1 ±2.9 ngj 
ml at 8:00 hof day 2 to 125±68 ng/ml at 15:00 h 
of day 3. 
Discussion 
In this study etomidate was successfully employed 
to correct the hypercortisolemia of Cushing's syn-
drome without unwarranted hypnotic side effects. 
Independent of baseline levels cortisol was sup-
pressed to within the normal range with as little 
as 2.5 mg/h etomidate. Although the cortisol re-
sponse to exogenous ACTH was not completely 
blocked at this dose, no escape of serum cortisol 
was found, as no increase in endogenous ACTH 
secretion occurred. 
A failure of ACTH to rise in response to adre-
nostatic therapy in Cushing's disease has also been 
observed during administration of ketoconazole, 
another imidazole derivative [14], as well as during 
long-term treatment with metyrapone and amino-
glutethimide [11]. This phenomenon probably re-
flects the autonomous nature of ACTH secretion 
by the pituitary tumor, rather than a direct sup-
pressive action of these substances at the pituitary 
level [15]. 
When etomidate was given in a dose of 0.3 mgj 
kgjh, responsiveness of cortisol to exogenous 
ACTH was rapidly lost, making this dosage at first 
glance even more attractive for control of hyper-
cortisolemia. However, in contrast to the findings 
of Engelhardt et al. [6] in normal subjects, sedation 
was observed in two of the three patients studied. 
Thus, at this dose only a small margin separates 
the adrenostatic action of etomidate from its po-
tent hypnotic properties. This was amply dem on-
strated in another patient wirh an adrenal ade-
noma in whom incorrect handling of the more 
highly concentrated etomidate solution led to a 
short period of deep sedation. Moreover, for infu-
sion of etomidate at a dose ofO.3 mgjkgjh a special 
preparation of etomidate dissolved in ethanol is 
necessary, which was introduced only for investiga-
tional use in long-term sedation and is not gene-
rally available. These difficulties and the observa-
tion that steady-state concentrations of cortisol du-
ring infusion with etomidate were rather similar 
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with the two different dosages make 0.3 mg/kg/h 
etomidate less suitable for treatment of hypercorti-
solemia. 
Etomidate for induction of anesthesia is dissol-
ved in propyleneglycol. Because of possible hema-
tolytic side effects of this solvent, no more than 
80 mg of etomidate should be administered within 
24 h according to the guidelines of the manufactu-
rer. Given as a continuous infusion this equals a 
dose of 3.3 mg/h, which is 33% higher than the 
dose successfully used in our study. Thus, the wider 
margin of safety and the availability suggest that 
a dose of 80 mg/24 h (0.04-0.05 mg/kg/h) should 
be infused for rapid correction of hypercortisole-
mia in Cushing's syndrome. 
Adrenostatic therapy of Cushing's syndrome is 
of limited value as in this disease surgical removal 
of the underlying cause is the ultimate therapeutic 
goal. However, long-term treatment with adreno-
static agents has been shown to be feasible in a 
number of studies [4, 11, 13, 16] and may be the 
treatment of choice for ectopic Cushing's syn-
drome in the presence of extensive disease [16]. 
Moreover, clinical improvement achieved by adre-
nostatic agents may favorably influence the results 
of later surgery. In the severely ill patient with 
Cushing's syndrome, rapid contro! of hypercorti-
solemia may be mandatory to avoid serious com-
plications due to hypokalemia or psychosis and, 
thus, be aprerequisite for further management. 
Here etomidate may become the drug of choice 
because it is the only adrenostatic agent which can 
be administered intravenously while lacking the 
side effects frequently encountered with other adre-
nostatic agents. 
In conclusion, low-dose etomidate has been 
shown to correct the hypercortisolemia of Cush-
ing's syndrome without hypnotic side effects. As 
etomidate is the only adrenostatic agent which can 
be given intravenously it appears to be especially 
suitable for the initial therapy of the severely ill 
patient with Cushing's syndrome, in a therapeutic 
dose of 0.04-0.05 mgjkgjh. 
Acknowledgements: We are grateful to Ms. D. Vollmar, H. 
Hofmann, and G. RoBbach for skilful technical assistance. 
High-dose etomidate was a gift of Fa. Janssen, NeuB, FRG 
References 
1. Allolio B, Winkelmann W, Hipp FX (1980) Effect ofmecla-
stine, an Hcantihistaminc, on plasma ACTH in adrenal 
insufficiency. Acta Endocrinol 96:98-101 
2. Allolio B, Stuttmann R, Leonhard U, Fischer H, Winkel-
mann W (1984) Adrenoeortical suppression by a single in-
duction dose of etomidate. Klin Wochenschr 62: 1014-1017 
B. Allolio et al.: Etomidate for Cushing's Syndrome 
3. Allolio B, Dörr H, Stuttmann R, Knorr D, Engelhardt D, 
Winkelmann W (1985) Effect of a single bolus of etomidate 
upon eight major corticosteroid hormones and plasma 
ACTH. Clin EndocrinoI22:281-286 
4. Child DF, Burke CW, Burley DW, Rees LH, Fraser TR 
(1985) Drug control of Cushing's syndrome. Acta Endocri-
no182:330-341 
5. De Coster R, Beerens D, Haelterman C, Wouters L (1985) 
Effects of etomidate on cortisol biosynthesis in iso la ted gui-
nea-pig adrenal cells: comparison with metyrapone. J En-
docrinol Invest 8: 199-202 
6. Engelhardt D, Stuttmann H, Jacob K, Dörr HG (1986) 
Influence of low-dose etomidate on adrenal and gonadal 
steroid hormone secretion in normal men. Acta Endocrinol 
[SuppI274] 111 :21-22 
7. Fragen RJ, Shanks CA, Molteni A, Avram MJ (1984) Ef-
fects of etomidate on hormonal responses to surgical stress. 
Anesthesiology 61 : 652-656 
8. Fry DE, Griffiths H (1984) The inhibition by etomidate 
of the 11 ß-hydroxylation of cortisol. Clin Endocrinol 
20:625-629 
9. Gärtner R, Albrecht M, Müller OA (1986) Effect of etomi-
date on hypercortisolism due to ectopic ACTH production. 
Lancet I: 275 
10. Hebron BS, Edbrooke DL, Newby DM, Mather SJ (1983) 
Pharmacokinetics of etomidate associated with prolonged 
Lv. infusion. Br J Anaesth 55:281-285 
11. Jeffcoate WJ, Rees LH, Tomlin S, Jones AE, Edwards 
CRW, Besser GM (1977) Metyrapone in long-term manage-
ment ofCushing's disease. Br Med J 2:215-217 
12. Kenyon CJ, Young J, Gray CE, Fraser R (1984) Inhibition 
by etomidate of steroidogenesis in isolated bovine adrenal 
cells. J Clin Endocrinol Metab 58: 947-949 
13. Lambert A, Mitchell R, Forst J, Ratcliffe JG, Robertson 
WR (1983) Direct in vitro inhibition of adrenal steroidoge-
ncsis by etomidate. Lancet II: 1085-1086 
14. Loli P, Berselli ME, Tagliaferri M (1986) Use of ketocona-
zole in the treatment of Cushing's syndrome. J Clin Endoc-
rinol Metab 63: 1365-1370 
15. Stalla GK, Stalla J, Huber M, Müller OA (1987) Ketocona-
zole inhibits cAMP generation and ACTH secretion in rat 
anterior pituitary cell culture. Acta Endocrinol [Suppl 283] 
114:32-33 
16. Thoren M, Adamson U, Sjöberg HE (1985) Aminoglutethi-
mide and metyrapone in the management of Cushing's syn-
drome. Acta EndocrinoI109:451-457 
17. Vanden Bossche H, Willemsens G, Cools W, Bellens D 
(1984) Effects of etomidate on steroid biosynthesis in subcel-
lular fractions of bovine adrenaJs. Biochem Pharmacol 
33:3861-3868 
18. Voigt KH, Fehm HL, Reck R, Pfeiffer EF (1974) Sponta-
neous and stimulated secretion of Quso-cxtractable immu-
noassayable ACTH in man. Klin Wochenschr 52:516-521 
19. Wagner RL, White PF, Kan PB, Rosenthai MH, Feldman 
MD (1984) Inhibition of adrenal steroidogenesis by the an-
esthetic etomidate. N Engl J Med 310: 1415-1421 
Received: September 7, 1987 
Returned for revision: October 27,1987 
Accepted: January 19,1988 
Dr. B. Allolio 
Medizinische Klinik 
Ostmerheimer Straße 200 
D-5000 Köln 91 
